Drag a card by its title · ⚙ to size, swap or remove

The company

Opus Genetics, Inc.

IRD · Nasdaq

Health CareBiotechnologyNot moving yet

IRD stood above a rising 150-day average in 42 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 13.3% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 1
Industry in uptrend: 16% -15 in 4 wk
Insider buys, 12 months: $324K
Insider sales, 12 months: $27.3M
Officials’ trades on record: 0
Institutions holding: 100 (+24)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 42 of 52 weeks.

20 Apr – 19 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1

Sale orders, 12 months18

Buyers · sellers1 · 7

Who	Did	Shares	Traded
Foundation Fighting Blindness Retinal Degeneration FundDirector, Other	sold	556,000at $4.96	30 Sep 2026filed 2 Oct 2026
Robert E. GagnonChief Financial Officer	sold	28,000at $4.54	3 Sep 2026filed 8 Sep 2026
Robert E. GagnonChief Financial Officer	sold	7,783at $2.95	23 Jul 2026filed 27 Jul 2026
George MagrathChief Executive Officer	sold	9,475at $2.95	23 Jul 2026filed 27 Jul 2026
Joseph K. SchachleChief Operating Officer	sold	4,644at $2.94	23 Jul 2026filed 27 Jul 2026
Benjamin R. YerxaPresident	sold	7,429at $2.97	23 Jul 2026filed 27 Jul 2026
Foundation Fighting Blindness Retinal Degeneration FundDirector, Other	sold	1,700,000at $4.35	18 May 2026filed 20 May 2026
Robert E. GagnonChief Financial Officer	sold	7,842at $5.18	23 Apr 2026filed 27 Apr 2026
Ashwath JayagopalChief Scientific & Dev. Ofc.	sold	7,542at $5.19	23 Apr 2026filed 27 Apr 2026
George MagrathChief Executive Officer	sold	9,511at $5.22	23 Apr 2026filed 27 Apr 2026
Rabourn Amy ZarembaHead of Fin. Quality Assurance	sold	1,641at $5.20	23 Apr 2026filed 27 Apr 2026
Joseph K. SchachleChief Operating Officer	sold	4,697at $5.22	23 Apr 2026filed 27 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders100+24 on the quarter

New · exited38 · 15

Reported value$236.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
Caligan Partners LPadded · filed 14 Aug 2026	6,077,084$25.0M	+2,0560.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.unchanged · filed 14 Aug 2026	6,029,775$24.8M	00.0%
BIOS Capital Management, LPunchanged · filed 14 Aug 2026	3,683,429$15.1M	00.0%
BlackRock, Inc.added · filed 7 Aug 2026	3,116,487$12.8M	+2,968,747+2009.4%
Balyasny Asset Management L.P.added · filed 14 Aug 2026	3,087,866$12.7M	+369,837+13.6%
Nantahala Capital Management, LLCadded · filed 14 Aug 2026	3,061,359$12.6M	+1,380,029+82.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	2,958,683$12.2M	+508,696+20.8%
Boxer Capital Management, LLCadded · filed 14 Aug 2026	2,815,000$11.6M	+565,000+25.1%
Trails Edge Capital Partners, LPadded · filed 14 Aug 2026	2,743,658$11.3M	+2,243,658+448.7%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026	2,302,101$9.5M	-328,331−12.5%